Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Brain scans of patients with NMDAR-antibody encephalitis © UCL/University of Oxford

Laboratory studies have shown that these antibodies can cause NMDA receptors to be removed from the cell surface into the cell, interfering with signals between them.

But a new study has now shown this directly in patients with this condition.

The research, led by UCL working with a team from Oxford, involved specialised PET-magnetic resonance scans on five people recovering from the condition and 29 healthy volunteers.

It found that in the early phase of recovery the receptors are not as available in affected patients, but came back to normal levels after full recovery in another patient.

The paper has been published in JAMA Neurology and authored by a team including researchers from Oxford University’s Nuffield Department of Clinical Neuroscience (Professor Sarosh Irani) and the Department of Psychiatry (Dr Adam Al-Diwani).

Dr Al-Diwani said:

 

“Understanding the effect on receptors helps inform our understanding of how the antibodies cause the condition, and may help improve treatments in the future.”

Symptoms of NMDAR-antibody encephalitis include changes in mental state that can be confused with a psychiatric illness, before patients develop seizures and a movement disorder.

 

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Collaboration with the Nepal Public Health Foundation (NPHF) explores maternal health and epilepsy

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.